Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.

Costa-Frossard L, Brieva L, García-Estévez DA, Martín-Martínez JM, Álvarez-Bravo G, Blasco-Quílez MR, Meca-Lallana JE, Calles-Hernández MC, Ramo Tello C, Muñoz-Fernández C, Barbero DE, López-Muñoz P, Prieto González JM, Candeliere-Merlicco A, Carmona O, Riancho J, Sola-Valls N, Carcelén-Gadea M, Borrega L, Gascón-Giménez F, Vilanova D, Pérez X, Villar LM

Open source

DOI: 10.3390/ijms27114933
Published: 2026 May 29
Container: International journal of molecular sciences
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/ijms27114933,
  title = {Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.},
  author = {Costa-Frossard L and Brieva L and García-Estévez DA and Martín-Martínez JM and Álvarez-Bravo G and Blasco-Quílez MR and Meca-Lallana JE and Calles-Hernández MC and Ramo Tello C and Muñoz-Fernández C and Barbero DE and López-Muñoz P and Prieto González JM and Candeliere-Merlicco A and Carmona O and Riancho J and Sola-Valls N and Carcelén-Gadea M and Borrega L and Gascón-Giménez F and Vilanova D and Pérez X and Villar LM},
  year = {2026},
  journal = {International journal of molecular sciences},
  doi = {10.3390/ijms27114933},
  url = {https://doi.org/10.3390/ijms27114933}
}

RIS

TY  - JOUR
TI  - Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.
AU  - Costa-Frossard L
AU  - Brieva L
AU  - García-Estévez DA
AU  - Martín-Martínez JM
AU  - Álvarez-Bravo G
AU  - Blasco-Quílez MR
AU  - Meca-Lallana JE
AU  - Calles-Hernández MC
AU  - Ramo Tello C
AU  - Muñoz-Fernández C
AU  - Barbero DE
AU  - López-Muñoz P
AU  - Prieto González JM
AU  - Candeliere-Merlicco A
AU  - Carmona O
AU  - Riancho J
AU  - Sola-Valls N
AU  - Carcelén-Gadea M
AU  - Borrega L
AU  - Gascón-Giménez F
AU  - Vilanova D
AU  - Pérez X
AU  - Villar LM
PY  - 2026
JO  - International journal of molecular sciences
DO  - 10.3390/ijms27114933
UR  - https://doi.org/10.3390/ijms27114933
ER  -

APA

L, C., L, B., DA, G., JM, M., G, Á., MR, B., JE, M., MC, C., C, R. T., C, M., DE, B., P, L., JM, P. G., A, C., O, C., J, R., N, S., M, C., L, B., F, G., D, V., X, P., & LM, V. (2026). Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.. International journal of molecular sciences. https://doi.org/10.3390/ijms27114933

Source records

pubmed · retrieved 2026-09-27T09:36:24.308Z